Qi R, Fu X, Yu Y, Xu H, et al. Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study. Lung Cancer 2023;184:107346.
PMID: 37604026